STOCK TITAN

Heron Therapeutics to Report Second Quarter 2023 Financial Results on Monday, August 14, 2023

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences earnings
Rhea-AI Summary
Heron Therapeutics, Inc. (HRTX) to host conference call and webcast to report Q2 2023 financial results and business highlights
Positive
  • None.
Negative
  • None.

SAN DIEGO, Aug. 7, 2023 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing therapeutic innovations that improve medical care, today announced that the company will host a conference call and live webcast on Monday, August 14, 2023 at 4:30 p.m. ET to report second quarter 2023 financial results and discuss recent business highlights.

The conference call can be accessed by dialing (646) 307-1963 in the U.S. or (800) 715-9871 internationally. Please provide the operator with the passcode 5410567 to join the conference call. The conference call will also be available via webcast under the Investor Relations section of Heron's website at www.herontx.com. An archive of the teleconference and webcast will also be made available on Heron's website for 60 days following the call.

About Heron Therapeutics, Inc.

Heron Therapeutics, Inc. is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs. Our advanced science, patented technologies, and innovative approach to drug discovery and development have allowed us to create and commercialize a portfolio of products that aim to advance the standard-of-care for acute care and oncology patients. For more information, visit www.herontx.com.

Forward-looking Statements

This news release contains "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995. Heron cautions readers that forward-looking statements are based on management's expectations and assumptions as of the date of this news release and are subject to certain risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include, but are not limited to, risks and uncertainties identified in the company's filings with the Securities and Exchange Commission. Forward-looking statements reflect our analysis only on their stated date, and Heron takes no obligation to update or revise these statements except as may be required by law.

Investor Relations and Media Contact:

Ira Duarte
Executive Vice President, Chief Financial Officer
Heron Therapeutics, Inc.
iduarte@herontx.com
858-251-4400

(PRNewsfoto/Heron Therapeutics, Inc.)

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/heron-therapeutics-to-report-second-quarter-2023-financial-results-on-monday-august-14-2023-301894889.html

SOURCE Heron Therapeutics, Inc.

Heron Therapeutics, Inc. will report its Q2 2023 financial results on Monday, August 14, 2023 at 4:30 p.m. ET.

The conference call can be accessed by dialing (646) 307-1963 in the U.S. or (800) 715-9871 internationally. The webcast will be available under the Investor Relations section of Heron Therapeutics, Inc.'s website at www.herontx.com.

Yes, an archive of the teleconference and webcast will be available on Heron Therapeutics, Inc.'s website for 60 days following the call.
Heron Therapeutics, Inc.

NASDAQ:HRTX

HRTX Rankings

HRTX Latest News

HRTX Stock Data

375.82M
122.02M
0.93%
76.01%
17%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
SAN DIEGO

About HRTX

heron therapeutics, inc. (formerly a.p. pharma, inc.) is a specialty pharmaceutical company developing products using its proprietary biochronomer™ polymer-based drug delivery platform. this drug delivery platform is designed to improve the therapeutic profile of injectable pharmaceuticals by converting them from products that must be injected once or twice per day to products that need to be injected only once every one or two weeks.